Sandbox leucocytosis: Difference between revisions
No edit summary |
No edit summary |
||
Line 750: | Line 750: | ||
| rowspan="7" style="background: #DCDCDC; padding: 5px; text-align: left;" | | | rowspan="7" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Epithelial tissue origin | * Epithelial tissue origin | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Squamous cell carcinoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 757: | Line 758: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Basal cell carcinoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 764: | Line 766: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Verrucous crcinoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 771: | Line 774: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Spindle cell carcinoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 778: | Line 782: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Adenoid squamous cell carcinoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 785: | Line 790: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Lymphoepithelioma and transitional cell carcinoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 792: | Line 798: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Malignant melanoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 801: | Line 808: | ||
| style="background: #DCDCDC; padding: 5px; text-align: left;" | | | style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Nerve tissue origin | * Nerve tissue origin | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Malignant schwannoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 810: | Line 818: | ||
| rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | | rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Muscle tissue origin | * Muscle tissue origin | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Leiomyosarcoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 817: | Line 826: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Rhabdomyosarcoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 826: | Line 836: | ||
| rowspan="7" style="background: #DCDCDC; padding: 5px; text-align: left;" | | | rowspan="7" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Lymphoid tissue origin | * Lymphoid tissue origin | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Malignant lymphoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 833: | Line 844: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Non Hodgkin lymphoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 840: | Line 852: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Hodgkin lymphoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 847: | Line 860: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
*Burkitt's lymphoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 854: | Line 868: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Reticular cell sarcoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 861: | Line 876: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
| style="background: #DCDCDC; padding: 5px; text-align: | * Plasma cell tumor | ||
| style="background: #DCDCDC; padding: 5px; text-align: left;"| | |||
* Multiple myeloma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 869: | Line 886: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;"| | ||
* Plasmacytoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 878: | Line 896: | ||
| rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | | rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Connective and Adipose tissue origin | * Connective and Adipose tissue origin | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Fibrosarcoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 885: | Line 904: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Liposarcoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 894: | Line 914: | ||
| rowspan="6" style="background: #DCDCDC; padding: 5px; text-align: left;" | | | rowspan="6" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Tumors of disputed origin | * Tumors of disputed origin | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Granular cell myoblastoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 901: | Line 922: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Congenital epulis | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 908: | Line 930: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Alveolar soft part sarcoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 915: | Line 938: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Melanocytic neuroectodermal tumor of infancy | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 922: | Line 946: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Kaposi sarcoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 929: | Line 954: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Ewing's sarcoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 943: | Line 969: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Herpes simplex virus | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 950: | Line 977: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Varicella zoster virus | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 957: | Line 985: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Coxsackie virus | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 964: | Line 993: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* HIV infection | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 971: | Line 1,001: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Syphilis | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 978: | Line 1,009: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Other infections | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 992: | Line 1,024: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Oral erosive lichen planus | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 999: | Line 1,032: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Systemic lupus erythamtosus | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,006: | Line 1,040: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Mucus membrane pemphigoid | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,013: | Line 1,048: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Bullous pemphigoid | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,020: | Line 1,056: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Pemphigus vulgaris | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,027: | Line 1,064: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Paraneoplastic pemphigus | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,034: | Line 1,072: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Epidermolysis bullosa acquisita | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,048: | Line 1,087: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Burning mouth syndrome | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,055: | Line 1,095: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Contact stomatitis | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,062: | Line 1,103: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Cheilitis | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,069: | Line 1,111: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Mucoceles | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,076: | Line 1,119: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Torus | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,083: | Line 1,127: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Dental erosions/Gingival overgrowth | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,090: | Line 1,135: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Telangiectasias | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,097: | Line 1,143: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: | ! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: left;" |Tongue lesions | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features | ||
Line 1,104: | Line 1,150: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Atrophic glossitis | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,111: | Line 1,158: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Fissured tongue | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,118: | Line 1,166: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Black tongue | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,125: | Line 1,174: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Black hairy tongue | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,132: | Line 1,182: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Pigmented fungiform papillae of the tongue | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,139: | Line 1,190: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Geographic tongue | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 1,146: | Line 1,198: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Median rhomboid glossitis | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | |
Revision as of 20:42, 23 January 2019
Disease | Presentation | Risk Factors | Diagnosis | Affected Organ Systems | Important features | Picture |
---|---|---|---|---|---|---|
Diseases predominantly affecting the oral cavity | ||||||
Oral Candidiasis |
|
|
|
Localized candidiasis
Invasive candidasis |
|
|
Herpes simplex oral lesions |
|
|
|
|
||
Aphthous ulcers |
|
|
|
|
|
|
Squamous cell carcinoma |
|
|
||||
Leukoplakia |
|
|
|
|
||
Melanoma |
|
|
|
|
||
Fordyce spots |
|
|
|
|
||
Burning mouth syndrome |
|
|
||||
Torus palatinus |
|
|||||
Diseases involving oral cavity and other organ systems | ||||||
Behcet's disease |
|
|
|
|||
Crohn's disease |
|
|
|
|||
Agranulocytosis |
|
|
||||
Syphilis |
|
|
|
|||
Coxsackie virus |
|
|
||||
Chicken pox |
|
|
|
|
||
Measles |
|
|
|
|
Normal variant oral lesions | Localization | Differentiating features | Diagnostic procedure | Treatment | |||
---|---|---|---|---|---|---|---|
|
|||||||
|
|||||||
Benign Oral lesions | Localization | Differentiating features | Diagnostic procedure | Treatment | |||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|
||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|
|
|||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|
||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
Pre-malignant oral lesions | Localization | Differentiating features | Diagnostic procedure | Treatment | |||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
Malignant oral lesions | Localization | Differentiating features | Diagnostic procedure | Treatment | |||
|
|
||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|
||||||
|
|
||||||
|
|||||||
|
|
||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|
||||||
|
|||||||
|
|
||||||
|
|||||||
|
|
||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
Infections | Localization | Differentiating features | Diagnostic procedure | Treatment | |||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
Autoimmune Conditions | Localization | Differentiating features | Diagnostic procedure | Treatment | |||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
Miscellaneous | Localization | Differentiating features | Diagnostic procedure | Treatment | |||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
Tongue lesions | Localization | Differentiating features | Diagnostic procedure | Treatment | |||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
|||||||
|
Type of cancer | Subtype | Epidemiology | Localization | Clinical features | Diagnostic procedures |
---|---|---|---|---|---|
Squamous cell carcinoma
|
Verrucous carcinoma |
|
|
|
Biopsy shows:
Thickened club-shaped papillae and blunt stromal invaginations of well-differentiated squamous epithelium with marked keratinization |
Lymphoepithelial carcinoma | 0.8-2% of all oral or oropharyngeal cancers |
|
|
Biopsy chows:
| |
Epithelial precursor lesions | --- | --- | Seen in the entire digestive tract |
|
Biopsy shows:
|
Proliferative verrucous leukoplakia and precancerous conditions | --- |
|
|
An aggressive form of oral leukoplakia with considerable morbidity and
strong predilection to malignant transformation |
Biopsy shows:
|
Papillomas | Squamous cell papilloma and |
|
Any oral site may be affected mostly:
|
Soft, pedunculated lesions formed by a cluster of finger-like fronds or a sessile, dome-shaped lesion with a nodular, papillary or verrucous surface | Biopsy shows:
|
Condyloma acuminatum | 2nd and 5th decade with a peak in teenagers and young adults |
|
Biopsy shows:
Several sessile, cauliflower-like swellings forming a cluster | ||
Focal epithelial hyperplasia | Disease of children, adolescents and young adults |
|
|
Biopsy shows:
| |
Granular cell tumor | --- |
|
|
|
Biopsy shows:
|
Keratoacanthoma | --- |
whites
men as in women |
|
|
Biopsy shows:
|
Papillary hyperplasia | --- | Affects all age groups | Palate | Asymptomatic nodular or papillary mucosal lesion | Biopsy shows:
|
Median rhomboid glossitis | --- | --- | Dorsum of the tongue at the junction of the anterior two thirds
and posterior third |
Forms a patch of papillary atrophy in the region of the
embryological foramen caecum |
Biopsy shows:
|
Salivary gland tumors | Acinic cell carcinoma |
|
Tumors usually
form non-descript swellings |
Biopsy shows:
| |
Mucoepidermoid carcinoma |
|
|
|
Low power microscopy shows low-grade tumor with both cystic and solid areas and an inflamed, fibrous stroma | |
Adenoid cystic carcinoma |
|
|
Predominantly solid variant shows peri- and intraneural invasion | ||
Epithelial-myoepithelial
carcinoma |
--- | --- | --- | --- | |
Clear cell carcinoma,
NOS |
--- | --- | --- | ||
Basal cell | Rare in minor glands | Asymptomatic, smooth or lobulated sub-mucosal masses | Microscopically similar to basal
cell adenocarcinomas of the major gland | ||
Cystadenocarcinoma | 32% developed in the minor glands |
|
Slow growing and painless but
some palatal tumors may erode the underlying bone causing sinonasal complex |
--- | |
Salivary duct carcinoma |
|
|
Tumors formed painless swellings but many in the palate can be painful and ulcerated or fungated with metastases to regional lymph nodes | The range of
microscopical appearances is similar to that seen in the major glands | |
Salivary gland adenomas | Pleomorphic adenoma | 40-70% of minor gland tumors |
|
Painless, slow growing, submucosal masses, but when | Biopsy shows cellular, and hyaline or plasmacytoid cell |
Myoepithelioma | 42% of minor gland tumors |
|
--- | --- | |
Basal cell adenoma | 20% of minor gland tumors | --- | They are histologically
similar to those in major glands. | ||
Cystadenoma | 7% of benign minor gland tumors | --- | --- | ||
Kaposi sarcoma | --- |
|
|
Biopsy of all 4 types show:
| |
Lymphangioma | --- |
|
Tongue |
|
Biopsy shows:
|
Ectomesenchymal chondromyxoid
tumour of the anterior tongue |
--- |
|
--- | Asymptomatic, slow growing solitary nodule in the anterior dorsal tongue | Biopsy shows:
|
Focal oral mucinosis (FOM) | --- |
|
Asymptomatic fibrous or cystic-like lesion | Histopathology is characterized by:
| |
Congenital granular cell epuli | --- |
|
Solitary, somewhat pedunculated fibroma-like lesion attached to the alveolar
ridge near the midline |
||
Hematolymphoid tumors | Non-Hodgkin lymphoma | Second most common cancer of the oral cavity |
|
NHL of the lip presents with:
|
Biopsy shows:
|
Langerhans cell histiocytosis | --- |
and |
Common oral symptoms
include:
|
Biopsy shows ovoid Langerhans cells
with deeply grooved nuclei, thin nuclear membranes and abundant eosinophilic cytoplasm | |
Hodgkin lymphoma | --- |
|
Most patients present with localized disease (stage I/II), with
|
--- | |
Extramedullary myeloid
sarcoma |
--- | Isolated tumor-forming intraoral mass | Biopsy shows an Indian-file pattern of infiltration | ||
Follicular dendritic cell
sarcoma / tumour |
|
|
The patients usually
present with a painless mass |
Biopsy usually exhibits
borders and comprises:
| |
Mucosal malignant melanoma | --- |
|
80% arise:
Others:
|
|
|